General Electric and Pfizer -- Dividend Growth Plays for 2012
Five Star Equities Provides Stock Research on General Electric and Pfizer
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 01/12/12 -- Dividend payments have been rising strongly in recent quarters. Companies listed in the Standard & Poor's 500-stock index paid $240.6 billion in dividends in 2011, up from $205 billion in 2010, The New York Times reports. As the New Year kicks off, data released by S&P says that dividends are on track to set a record of more than $252 billion in 2012. Five Star Equities examines the outlook for blue chip dividend paying companies and provides equity research on General Electric Co. (NYSE: GE) & Pfizer, Inc. (NYSE: PFE). Access to the full company reports can be found at:
General Electric currently pays an annual dividend of 68 cents for a yield of around 3.6 percent. Sterne Agee analyst Ben Elias issued a report earlier this month arguing that General Electric should be able to maintain a 45% dividend payout, and possibly buyback stock in 2012.
General Electric operates as a technology, service, and finance company worldwide. GE Capital's Telecom, Media and Technology (TMT) financing business announced earlier this week that it completed 38 deals totaling $3.4 billion in financing during 2011.
Five Star Equities releases regular market updates on blue chip dividend paying companies so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. Pfizer presently pays an annual dividend of 80 cents for a hefty yield of around 3.7 percent. Earlier this week the company's CEO Ian Read says that Pfizer's Lipitor cholesterol drug is, "basically where we expected to be," holding onto ~37%-38% of the overall U.S. market while competing with generic versions.
Generic versions of Lipitor from Watson Pharmaceuticals Inc. and Ranbaxy Laboratories Ltd. went on sale in late November and early December, marking the loss of U.S. exclusivity for Pfizer's Lipitor.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
Contact:
Five Star Equities
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.01.2012 - 13:20 Uhr
Sprache: Deutsch
News-ID 103561
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"General Electric and Pfizer -- Dividend Growth Plays for 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Five Star Equities (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
